Dupilumab in COPD: A Pooled Analysis of Emergency Department Visits, Hospital Admissions, and Systemic Corticosteroid Use.

Summary

In pooled phase 3 RCTs of COPD with type 2 inflammation (eosinophils ≥300/µL), dupilumab reduced emergency department visits/hospital admissions by 38% and delayed time to first event (HR 0.55) over 52 weeks. Systemic corticosteroid use during moderate and severe exacerbations was reduced by 28% and 42%, respectively.

Key Findings

• Dupilumab reduced ED visits/hospital admissions of any duration by 38% versus placebo (RR 0.62; 95% CI 0.43–0.90; P=0.0121).
• Time to first ED visit/hospital admission was delayed, with a 45% reduction in risk (HR 0.55; 95% CI 0.38–0.78; P=0.0010).
• Systemic corticosteroid use decreased by 42% in severe and 28% in moderate exacerbations compared with placebo.

Clinical Implications

For COPD patients with type 2 inflammation (eosinophils ≥300/µL), dupilumab may reduce emergency visits/hospitalizations and steroid burden, informing treatment selection and resource planning.

Limitations

• Pooled analysis; hospitalization endpoints may not have been primary in individual trials.
• Generalizability limited to COPD with blood eosinophils ≥300/µL; long-term safety and cost-effectiveness not addressed.

Future Directions

Head-to-head comparisons with other anti–type 2 agents, long-term safety and health-economics analyses, and evaluation in broader biomarker strata (e.g., 150–300 cells/µL).